Literature DB >> 34999722

Infographic: Everest II study "Which is superior? Combination therapy or monotherapy for polypoidal choroidal vasculopathy (PCV) treatment".

Chinmayi Himanshuroy Vyas1, Pooi Wah Lott1, Rubamalar Gunatheesan1, Shaun Sebastian Sim1,2, Christopher Ziyu Sun1, Kelvin Yi Chong Teo1,2, Chui Ming Gemmy Cheung3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34999722      PMCID： PMC9151653          DOI： 10.1038/s41433-021-01873-8

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  2 in total

1.  Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Authors:  Adrian Koh; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Chrystel Feller; Philippe Margaron; Tock H Lim; Won Ki Lee
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

2.  Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.

Authors:  Tock H Lim; Timothy Y Y Lai; Kanji Takahashi; Tien Y Wong; Lee-Jen Chen; Paisan Ruamviboonsuk; Colin S Tan; Won Ki Lee; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Ramune Patalauskaite; Philippe Margaron; Adrian Koh
Journal:  JAMA Ophthalmol       Date:  2020-09-01       Impact factor: 7.389
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.